Drug Repurposing Market
Report ID: SQMIG35J2561
Report ID: SQMIG35J2561
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2561 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
117
|Figures:
77
Global Drug Repurposing Market size was valued at USD 32.1 Billion in 2024 and is poised to grow from USD 33.54 Billion in 2025 to USD 51.8 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).
High demand for cost-effective drug development, increasing adoption of AI-driven drug discovery, rising investments in precision medicine, expanding regulatory support for repurposed therapies, and growing prevalence of chronic and rare diseases are driving sales of drug repurposing solutions.
Growing need to reduce drug development costs and accelerate the availability of effective therapies, coupled with increasing adoption of data-driven drug discovery approaches, is expected to primarily drive drug repurposing market growth. Rising use of approved drugs for new therapeutic indications across oncology, neurology, infectious diseases, and rare disorders is supporting market expansion. Increasing investments in genomics, real-world evidence platforms, artificial intelligence, and precision medicine are also contributing to growth. Continuous advancements in computational biology, target identification, biomarker research, and predictive analytics are further improving the success rate of repurposed therapies. In addition, supportive regulatory pathways and increasing collaborations between pharmaceutical and biotechnology companies are expected to create new growth opportunities for the market worldwide.
On the contrary, intellectual property limitations, regulatory and reimbursement challenges, limited commercial incentives for generic drugs, and clinical validation complexities are anticipated to slow down drug repurposing market penetration across the study period and beyond.
How is AI Accelerating Drug Repurposing Pipeline Efficiency In Pharmaceutical Companies?
AI is transforming the drug repurposing market by identifying new uses for existing drugs more quickly and efficiently. Machine learning analyzes electronic health records, genomic data, clinical studies, and real-world evidence to identify approved drugs with potential for treating different diseases. This significantly reduces the time needed to identify promising drug candidates and allows researchers to focus on the most effective therapies. AI also supports target validation, improves clinical trial planning, and speeds up regulatory processes by leveraging existing safety and efficacy data.
Market snapshot - (2026-2033)
Global Market Size
USD 32.1 Billion
Largest Segment
Disease Centric Approach
Fastest Growth
Drug Centric Approach
Growth Rate
4.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global drug repurposing market is segmented by approach type, therapeutic area, drug molecule, end user, and region. Based on approach type, the market is segmented into disease centric approach, target centric approach, and drug centric approach. Based on therapeutic area, the market is segmented into oncology, central nervous system diseases, infectious diseases, and rare diseases. Based on drug molecule, the market is segmented into small molecules and biologics. Based on end user, the market is segmented into pharmaceutical companies, academic research institutes, and contract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The disease centric approach segment is slated to lead the global drug repurposing market revenue generation across the study period. It is perfectly aligned to the clinical needs, making it possible for scientists to redirect pharmacology towards the disease pathways. It helps in generating hypotheses efficiently and minimizes risk at the earlier stage of development as it focuses on the patients' phenotypes and disease pathways. It provides a strong value proposition using huge disease registries and real-world evidence, leading to increased investment.
Meanwhile, target centric approach emerges as the fastest growing subsegment as per this drug repurposing industry analysis, due to advancements in target validation and AI-based binding predictions, it is now possible to quickly find such drug candidates. This trend helps to foster collaboration between biotech companies and platforms that provide data.
The oncology segment is forecasted to account for the highest global drug repurposing market share going forward. The relatively high levels of unmet need and rich history of data collection in cancer make this a promising area in which to repurpose existing compounds. Investigators will have access to substantial populations of patients, characterized molecular subtypes, and clinical trial frameworks, thus decreasing risk in drug development. Additionally, the possibility of extending the lifecycle of oncology drugs with new applications is consistent with pharma’ business strategies.
Conversely, central nervous system diseases segment is witnessing the strongest growth as a result of advancements in blood brain barrier models and neuropharmacology that have made it possible for certain compounds to be re-evaluated. With the development of new diagnostic biomarkers and technology platforms, faster patient recruitment is possible, coupled with more definitive regulatory pathways attracting investors.
To get detailed segments analysis, Request a Free Sample Report
Deep scientific expertise, substantial investment capital, and a regulatory environment that balances rigor with flexibility are helping shape the dominance of this region. North America houses a large number of biotech innovators and multinational pharmaceutical companies that place importance on diversifying their portfolio through the reuse of assets. Strong partnerships between public and private organizations in research speed up the process of target discovery, whereas a well-developed clinical trial system decreases time spent on the development process. Patient-centered care and government initiatives in Canada de-risk the initial phase of research. Both countries enjoy an established framework for reimbursement that rewards clinical value, hence increasing confidence to go to market. This virtuous circle of people, funding, and efficiency leads to dominance in the market.
Drug repurposing demand in United States benefits from an extensive network of research institutions, venture capital availability, and a mature regulatory pathway that accelerates the transition of repurposed candidates into clinical trials. The presence of major pharmaceutical headquarters fosters strategic collaborations, while reimbursement frameworks encourage adoption. Moreover, a culture of innovation and a sizable patient population support continuous pipeline generation and commercial viability across diverse therapeutic areas and disease models.
Drug repurposing market in Canada leverages strong public‑private partnerships and government incentives that de‑risk early‑stage projects. Top-ranked academic institutions and biotech clusters offer an excellent source of candidate compounds, while an efficient process of health technology assessment ensures a good avenue to the market. Collaboration in place between the provincial health organizations and the industry promotes information exchange, while the multilingual labor force helps coordinate international trials.
Tightly integrated research landscape, generous public funding, and harmonized regulatory standards that simplify cross-border development create new opportunities for drug repurposing providers in the region. Germany acts as the core of the region through world-class biomedical institutes and history of collaborative industry-academic efforts that have enabled excellent pipelines of candidates. The UK capitalizes on its early stage of clinical trial facilities along with the proactive health technology assessment body to hasten the process of approval of repurposed drugs. France provides a boost to the cause by incentivizing innovative drug discovery initiatives along with the emergence of biotech startups in the country. Data sharing is easier through networks among the EU, and the reimbursement systems are becoming increasingly receptive towards repurposed treatments due to their cost-effectiveness.
Drug repurposing market in Germany thrives on a robust network of university hospitals, research consortia, and established pharma giants that prioritize repositioning of existing compounds. Strong federal grants and tax incentives lower the financial barrier for early‑stage studies, while the German Medicines Agency offers clear guidance that expedites clinical assessment. Collaborative platforms encourage sharing of pre‑clinical data, enabling faster validation of therapeutic hypotheses across multiple disease areas and clinical translation.
Drug repurposing demand in United Kingdom benefits from a globally recognized clinical trial ecosystem and proactive health technology assessment mechanisms that streamline patient access. Centers of academic medicine work hand in hand with biotech developers to rapidly identify new applications for already known molecules. The funding agencies encourage translational science, and the regulatory guidance promotes the use of adaptive study designs. This environment facilitates shorter development timelines and greater commercial potential for the repurposed drugs.
Drug repurposing market in France is energized by strategic incentives that target early discovery and mid‑stage development of repositioned drugs. National research organizations work with new biotech companies to establish pipelines based on unmet medical needs. The French agency for health services offers adaptive assessment programs that give credit to previously accumulated clinical information. Tax credits and cluster cooperation minimize the risks, creating an enabling ecosystem for the development of repurposed products.
Strategic investments in precision medicine, a surge in digital health capabilities, and regulatory reforms that encourage innovative trial designs to support drug repurposing innovations in the region. With a history of highly developed research in pharmacology and patient-oriented health care systems that can embrace the use of repurposed drugs easily, Japan takes advantage of this potential. South Korea, with its highly developed biotech production capacities, also benefits from proactive government initiatives to support translational research by means of providing financial support. Collaboration between countries in the region facilitates the exchange of data from genome studies and real-life data, while reimbursement practices reward increasingly cost-effective medicines. This unique combination of science, policy, and open market makes Asia-Pacific region an emerging area of repurposed medicines development.
Drug repurposing market in Japan benefits from a deep scientific heritage and a well‑established pharmacovigilance framework that supports rapid assessment of known compounds. Government initiatives encourage academia‑industry partnerships, while the national health insurance system facilitates swift reimbursement for validated repurposed indications. Advanced data analytics and a culture of meticulous clinical methodology enhance the identification of novel therapeutic uses, positioning Japan as a leader in methodical drug repositioning in global health.
Drug repurposing market in South Korea is propelled by a dynamic biotech sector and governmental funding schemes that lower barriers for repurposing research. The country’s strong clinical trial infrastructure and accelerated approval pathways enable swift testing of existing drugs for new indications. Collaborative networks linking hospitals, universities, and contract research organizations foster rapid data generation, while emerging reimbursement strategies recognize the economic advantage of repurposed therapies, strengthening market uptake globally.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Innovation In Adaptive Trial Design
Collaborative Research Networks Are Expanding
Intellectual Property Uncertainties Limit Investment
Regulatory Hurdles Are Prolonging Approvals
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by intensified rivalry as firms leverage AI‑driven platforms, strategic M&A of niche repurposing pipelines, and partnerships with academic institutions to accelerate indication expansion, exemplified by recent collaborations that combine deep‑learning knowledge graphs with legacy drug libraries to secure faster regulatory pathways.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, increasing adoption of AI-driven drug discovery, rising investments in precision medicine, and expanding regulatory support for repurposed therapies are anticipated to drive the demand for drug repurposing going forward. However, intellectual property limitations and regulatory and reimbursement challenges are slated to slow down the adoption of drug repurposing in the future. North America is slated to spearhead the demand for drug repurposing owing to strong pharmaceutical research infrastructure, high investments in biotechnology, favorable regulatory support, and the presence of leading pharmaceutical and AI-driven drug discovery companies. AI-powered target identification and integration of real-world evidence with computational drug discovery are anticipated to be key trends driving the drug repurposing market over the coming years.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 32.1 Billion |
| Market size value in 2033 | USD 51.8 Billion |
| Growth Rate | 4.5% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Drug Repurposing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Drug Repurposing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Drug Repurposing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Drug Repurposing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Drug Repurposing Market size was valued at USD 32.1 Billion in 2024 and is poised to grow from USD 33.54 Billion in 2025 to USD 51.8 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).
The competitive landscape is shaped by intensified rivalry as firms leverage AI‑driven platforms, strategic M&A of niche repurposing pipelines, and partnerships with academic institutions to accelerate indication expansion, exemplified by recent collaborations that combine deep‑learning knowledge graphs with legacy drug libraries to secure faster regulatory pathways. 'BioXcel Therapeutics Inc', 'Rejuvenate Biomed NV', 'SOM Biotech SL', 'Granules India Limited', 'Every Cure Inc', 'NovaLead Pharma Pvt Ltd', 'Natco Pharma Limited', 'F Hoffmann La Roche AG', 'Indoco Remedies Limited', 'LifeArc Limited', 'Sanofi SA', 'GlaxoSmithKline plc', 'Eli Lilly and Company', 'Roche Holding AG', 'Novartis AG', 'Bayer AG', 'Arvinas Inc', 'BenevolentAI Limited', 'Recursion Pharmaceuticals Inc', 'UT Southwestern Medical Center'
The adoption of adaptive trial designs enables researchers to evaluate multiple drug candidates within a single study framework, accelerating data collection and reducing the time required to identify therapeutic efficacy. This methodological flexibility allows investigators to modify key parameters based on interim results, thereby conserving resources and minimizing patient exposure to ineffective treatments. Consequently, pharmaceutical firms can repurpose existing compounds more efficiently, fostering a rapid pipeline of candidates and strengthening confidence among investors and stakeholders. It also encourages cross‑disciplinary collaboration, which enriches the knowledge base required for successful drug repositioning.
Precision Medicine Integration: Pharmaceutical companies are increasingly pairing drug repurposing pipelines with genomic profiling and biomarker discovery to match existing compounds to niche patient subpopulations. This convergence accelerates hypothesis generation, reduces trial sizes, and improves success probabilities. Collaborative platforms linking academic data sets with commercial libraries enable rapid identification of mechanistic overlaps. As health systems adopt precision diagnostics, demand for tailored therapies grows, positioning repurposed agents as cost‑effective, targeted options that can be launched with limited regulatory friction and swift market entry timelines.
Why does North America Dominate the Global Drug Repurposing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
